Share Price and Basic Stock Data
Last Updated: January 24, 2026, 4:16 pm
| PEG Ratio | -35.38 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Laurus Labs Ltd operates within the pharmaceuticals industry, with a current market capitalization of ₹53,363 Cr and a share price of ₹988. The company has displayed a fluctuating yet upward trend in sales, which reported ₹5,773 Cr for the year ending March 2023, a growth from ₹4,707 Cr in the previous year. However, the sales forecast for FY 2024 shows a decline to ₹4,812 Cr, followed by a rebound to ₹5,217 Cr in FY 2025. Quarterly sales figures reveal variability, with a peak of ₹1,650 Cr expected in March 2025, compared to ₹1,279 Cr in March 2023. This highlights the company’s capacity to recover from setbacks, though the recent quarterly performance showed a drop to ₹1,108 Cr in June 2023 from ₹1,279 Cr in March 2023, indicating potential volatility in revenue generation. Overall, Laurus Labs’ sales demonstrate resilience, but the inconsistency in quarterly figures suggests challenges in maintaining steady growth.
Profitability and Efficiency Metrics
Laurus Labs’ profitability metrics reflect significant fluctuations, with a reported operating profit margin (OPM) of 26% in FY 2023, which fell to 16% in FY 2024 before recovering to 18% in FY 2025. The net profit for FY 2025 is projected at ₹380 Cr, following a net profit of ₹760 Cr in FY 2023. The interest coverage ratio (ICR) stood at a robust 5.55x, indicating a strong ability to cover interest expenses, which is favorable compared to industry standards. However, the return on equity (ROE) of 7.75% and return on capital employed (ROCE) of 9.47% are relatively low, suggesting room for improvement in capital efficiency. The cash conversion cycle (CCC) of 262 days indicates a longer duration for converting investments into cash flow, which can be detrimental to liquidity. Overall, while Laurus Labs shows potential for profitability, efficiency metrics reveal areas requiring strategic focus to enhance returns.
Balance Sheet Strength and Financial Ratios
The balance sheet of Laurus Labs demonstrates a solid foundation, with total assets reported at ₹8,587 Cr and total liabilities at ₹7,667 Cr for FY 2025. The company holds reserves of ₹4,810 Cr, which provides a cushion for operational and investment needs. Borrowings have increased to ₹2,380 Cr, yet the long-term debt to equity ratio is a manageable 0.14, reflecting prudent financial management. The price-to-book value ratio stands at 7.40x, indicating that the stock is trading at a premium compared to its book value. The current ratio is at 1.22, suggesting adequate short-term liquidity to meet obligations. Additionally, the asset turnover ratio of 0.62 indicates moderate efficiency in utilizing assets to generate revenue. Despite some concerns over high borrowing levels, the balance sheet remains strong, providing a solid base for future growth initiatives.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Laurus Labs reveals a diversified ownership structure, with promoters holding 27.60% and foreign institutional investors (FIIs) at 26.17%. Domestic institutional investors (DIIs) account for 11.72%, while the public holds 34.52%. The decrease in public shareholding from 41.38% in December 2022 to 34.52% in September 2025 may indicate a shift in investor sentiment. The fluctuation in FIIs, which increased from 21.90% in December 2022 to the current level, signals growing confidence among foreign investors. The total number of shareholders has also declined from 4,23,931 in December 2022 to 2,83,678, reflecting potential consolidation among investors. This trend could suggest either increased confidence in the company’s future or a response to recent performance volatility. Overall, while the investor base remains substantial, the declining public shareholding may warrant attention for maintaining broader market confidence.
Outlook, Risks, and Final Insight
The outlook for Laurus Labs presents a mixed scenario characterized by growth potential tempered by notable risks. On the positive side, the company is positioned to recover sales in FY 2025, with projected revenues of ₹5,217 Cr, driven by its strong product pipeline and capabilities in the pharmaceuticals sector. However, risks include fluctuating profitability margins, as evidenced by the drop in OPM and net profit projections, alongside a prolonged cash conversion cycle that may affect liquidity. Additionally, increasing borrowings could strain financial health if not managed properly. The company’s ability to enhance operational efficiency and leverage its strong balance sheet will be crucial for sustained growth. Should Laurus Labs successfully navigate these challenges, it could solidify its standing as a key player in the pharmaceutical industry, while failure to address these risks may hinder its potential.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.9 | 197/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,463 Cr. | 318 | 479/192 | 71.7 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.6 Cr. | 43.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 61.0 Cr. | 41.7 | 43.4/17.0 | 145 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,525.73 Cr | 1,087.19 | 47.43 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,498 | 1,501 | 1,279 | 1,108 | 1,158 | 1,132 | 1,415 | 1,117 | 1,185 | 1,265 | 1,650 | 1,433 | 1,567 |
| Expenses | 1,072 | 1,116 | 1,027 | 980 | 978 | 962 | 1,143 | 956 | 1,003 | 1,059 | 1,255 | 1,105 | 1,177 |
| Operating Profit | 426 | 385 | 252 | 128 | 181 | 170 | 271 | 161 | 182 | 206 | 395 | 327 | 390 |
| OPM % | 28% | 26% | 20% | 12% | 16% | 15% | 19% | 14% | 15% | 16% | 24% | 23% | 25% |
| Other Income | 4 | 3 | 6 | 7 | 6 | 11 | 24 | 9 | 12 | 7 | 72 | 22 | 28 |
| Interest | 38 | 39 | 41 | 33 | 38 | 38 | 42 | 41 | 45 | 48 | 49 | 44 | 34 |
| Depreciation | 76 | 78 | 81 | 84 | 85 | 87 | 89 | 91 | 91 | 89 | 88 | 94 | 96 |
| Profit before tax | 317 | 270 | 137 | 17 | 63 | 57 | 164 | 39 | 58 | 77 | 330 | 211 | 289 |
| Tax % | 28% | 26% | 25% | 24% | 26% | 25% | 26% | 26% | 27% | 25% | 24% | 25% | 25% |
| Net Profit | 227 | 199 | 102 | 13 | 47 | 43 | 121 | 29 | 42 | 57 | 252 | 158 | 216 |
| EPS in Rs | 4.23 | 3.70 | 1.90 | 0.24 | 0.87 | 0.79 | 2.25 | 0.53 | 0.79 | 1.06 | 4.67 | 2.93 | 4.00 |
Last Updated: December 30, 2025, 4:37 am
Below is a detailed analysis of the quarterly data for Laurus Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,567.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,433.00 Cr. (Jun 2025) to 1,567.00 Cr., marking an increase of 134.00 Cr..
- For Expenses, as of Sep 2025, the value is 1,177.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,105.00 Cr. (Jun 2025) to 1,177.00 Cr., marking an increase of 72.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 390.00 Cr.. The value appears strong and on an upward trend. It has increased from 327.00 Cr. (Jun 2025) to 390.00 Cr., marking an increase of 63.00 Cr..
- For OPM %, as of Sep 2025, the value is 25.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Jun 2025) to 25.00%, marking an increase of 2.00%.
- For Other Income, as of Sep 2025, the value is 28.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Jun 2025) to 28.00 Cr., marking an increase of 6.00 Cr..
- For Interest, as of Sep 2025, the value is 34.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 44.00 Cr. (Jun 2025) to 34.00 Cr., marking a decrease of 10.00 Cr..
- For Depreciation, as of Sep 2025, the value is 96.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 94.00 Cr. (Jun 2025) to 96.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 289.00 Cr.. The value appears strong and on an upward trend. It has increased from 211.00 Cr. (Jun 2025) to 289.00 Cr., marking an increase of 78.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 25.00%.
- For Net Profit, as of Sep 2025, the value is 216.00 Cr.. The value appears strong and on an upward trend. It has increased from 158.00 Cr. (Jun 2025) to 216.00 Cr., marking an increase of 58.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 4.00. The value appears strong and on an upward trend. It has increased from 2.93 (Jun 2025) to 4.00, marking an increase of 1.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:03 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,160 | 1,326 | 1,775 | 1,892 | 2,027 | 2,236 | 2,797 | 4,769 | 4,707 | 5,773 | 4,812 | 5,217 | 5,915 |
| Expenses | 951 | 1,121 | 1,402 | 1,478 | 1,618 | 1,884 | 2,226 | 3,258 | 3,421 | 4,292 | 4,062 | 4,273 | 4,596 |
| Operating Profit | 209 | 205 | 372 | 414 | 409 | 352 | 571 | 1,511 | 1,286 | 1,482 | 751 | 944 | 1,318 |
| OPM % | 18% | 15% | 21% | 22% | 20% | 16% | 20% | 32% | 27% | 26% | 16% | 18% | 22% |
| Other Income | 9 | 34 | 4 | 32 | 28 | 15 | 5 | 26 | 20 | 16 | 47 | 100 | 129 |
| Interest | 64 | 106 | 111 | 97 | 75 | 86 | 88 | 66 | 96 | 146 | 151 | 182 | 174 |
| Depreciation | 33 | 61 | 86 | 104 | 121 | 161 | 184 | 197 | 235 | 301 | 345 | 359 | 366 |
| Profit before tax | 121 | 72 | 180 | 245 | 241 | 121 | 304 | 1,275 | 975 | 1,051 | 301 | 504 | 907 |
| Tax % | 20% | -2% | 19% | 18% | 28% | 22% | 12% | 25% | 23% | 28% | 26% | 24% | |
| Net Profit | 97 | 74 | 145 | 200 | 173 | 95 | 267 | 956 | 750 | 760 | 224 | 380 | 683 |
| EPS in Rs | 12.64 | 9.47 | 18.36 | 3.78 | 3.27 | 1.78 | 5.00 | 17.82 | 13.96 | 14.12 | 4.15 | 7.05 | 12.66 |
| Dividend Payout % | 0% | 0% | 2% | 8% | 9% | 17% | 10% | 11% | 14% | 14% | 19% | 17% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -23.71% | 95.95% | 37.93% | -13.50% | -45.09% | 181.05% | 258.05% | -21.55% | 1.33% | -70.53% | 69.64% |
| Change in YoY Net Profit Growth (%) | 0.00% | 119.66% | -58.01% | -51.43% | -31.59% | 226.14% | 77.00% | -279.60% | 22.88% | -71.86% | 140.17% |
Laurus Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 13% |
| 3 Years: | 3% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 5% |
| 3 Years: | -23% |
| TTM: | 113% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 16% |
| 1 Year: | 79% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 17% |
| 3 Years: | 11% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 9:40 am
Balance Sheet
Last Updated: December 4, 2025, 1:34 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 16 | 16 | 106 | 106 | 106 | 107 | 107 | 107 | 108 | 108 | 108 | 108 |
| Reserves | 281 | 645 | 790 | 1,250 | 1,407 | 1,484 | 1,709 | 2,605 | 3,281 | 3,949 | 4,099 | 4,456 | 4,810 |
| Borrowings | 605 | 888 | 1,081 | 808 | 947 | 1,009 | 1,051 | 1,411 | 1,653 | 1,714 | 2,110 | 2,380 | 1,821 |
| Other Liabilities | 372 | 344 | 342 | 509 | 547 | 718 | 872 | 1,502 | 1,567 | 1,187 | 1,351 | 1,643 | 1,953 |
| Total Liabilities | 1,273 | 1,893 | 2,229 | 2,673 | 3,008 | 3,318 | 3,739 | 5,625 | 6,609 | 6,958 | 7,667 | 8,587 | 8,692 |
| Fixed Assets | 499 | 801 | 1,014 | 1,193 | 1,448 | 1,599 | 1,694 | 1,818 | 2,186 | 2,884 | 3,036 | 2,888 | 2,946 |
| CWIP | 116 | 107 | 70 | 143 | 163 | 107 | 67 | 324 | 755 | 357 | 156 | 336 | 438 |
| Investments | 0 | 19 | 26 | 51 | 52 | 58 | 58 | 319 | 362 | 384 | 635 | 740 | 807 |
| Other Assets | 658 | 966 | 1,119 | 1,286 | 1,345 | 1,554 | 1,920 | 3,164 | 3,306 | 3,333 | 3,841 | 4,623 | 4,501 |
| Total Assets | 1,273 | 1,893 | 2,229 | 2,673 | 3,008 | 3,318 | 3,739 | 5,625 | 6,609 | 6,958 | 7,667 | 8,587 | 8,692 |
Below is a detailed analysis of the balance sheet data for Laurus Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 108.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 108.00 Cr..
- For Reserves, as of Sep 2025, the value is 4,810.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,456.00 Cr. (Mar 2025) to 4,810.00 Cr., marking an increase of 354.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,821.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,380.00 Cr. (Mar 2025) to 1,821.00 Cr., marking a decrease of 559.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,953.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,643.00 Cr. (Mar 2025) to 1,953.00 Cr., marking an increase of 310.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8,692.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8,587.00 Cr. (Mar 2025) to 8,692.00 Cr., marking an increase of 105.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2,946.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,888.00 Cr. (Mar 2025) to 2,946.00 Cr., marking an increase of 58.00 Cr..
- For CWIP, as of Sep 2025, the value is 438.00 Cr.. The value appears strong and on an upward trend. It has increased from 336.00 Cr. (Mar 2025) to 438.00 Cr., marking an increase of 102.00 Cr..
- For Investments, as of Sep 2025, the value is 807.00 Cr.. The value appears strong and on an upward trend. It has increased from 740.00 Cr. (Mar 2025) to 807.00 Cr., marking an increase of 67.00 Cr..
- For Other Assets, as of Sep 2025, the value is 4,501.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,623.00 Cr. (Mar 2025) to 4,501.00 Cr., marking a decrease of 122.00 Cr..
- For Total Assets, as of Sep 2025, the value is 8,692.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,587.00 Cr. (Mar 2025) to 8,692.00 Cr., marking an increase of 105.00 Cr..
Notably, the Reserves (4,810.00 Cr.) exceed the Borrowings (1,821.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -396.00 | -683.00 | 371.00 | -394.00 | -538.00 | 351.00 | 570.00 | 0.00 | 0.00 | 0.00 | 749.00 | 942.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 78 | 91 | 108 | 100 | 112 | 102 | 98 | 98 | 94 | 124 | 142 |
| Inventory Days | 165 | 210 | 177 | 184 | 199 | 201 | 233 | 257 | 279 | 211 | 258 | 258 |
| Days Payable | 114 | 101 | 91 | 110 | 106 | 144 | 157 | 194 | 140 | 90 | 151 | 138 |
| Cash Conversion Cycle | 112 | 187 | 177 | 183 | 193 | 169 | 177 | 161 | 237 | 216 | 231 | 262 |
| Working Capital Days | -50 | -0 | 20 | 7 | -7 | 9 | 19 | 50 | 57 | 67 | 56 | 56 |
| ROCE % | 25% | 15% | 17% | 17% | 14% | 8% | 14% | 38% | 23% | 22% | 8% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Mirae Asset Large & Midcap Fund | 6,671,181 | 1.58 | 688.03 | N/A | N/A | N/A |
| Mirae Asset ELSS Tax Saver Fund | 5,023,466 | 1.9 | 518.1 | N/A | N/A | N/A |
| SBI Large & Midcap Fund | 3,800,000 | 1.06 | 391.91 | 5,392,600 | 2025-12-14 01:23:13 | -29.53% |
| Mirae Asset Midcap Fund | 2,822,588 | 1.58 | 291.11 | 3,071,035 | 2025-12-14 01:23:13 | -8.09% |
| Axis Small Cap Fund | 2,117,487 | 0.82 | 218.39 | 1,589,977 | 2025-12-08 03:11:13 | 33.18% |
| DSP Healthcare Fund | 1,914,476 | 6.21 | 197.45 | 2,217,884 | 2025-12-15 02:43:45 | -13.68% |
| SBI Healthcare Opportunities Fund | 1,400,000 | 3.5 | 144.39 | N/A | N/A | N/A |
| Mahindra Manulife Multi Cap Fund | 1,100,000 | 1.85 | 113.45 | 1,477,233 | 2025-12-14 01:23:13 | -25.54% |
| Tata Arbitrage Fund | 964,750 | 0.49 | 99.5 | 1,182,350 | 2025-12-14 01:23:13 | -18.4% |
| WhiteOak Capital Mid Cap Fund | 891,870 | 2.12 | 91.98 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 6.65 | 2.98 | 14.69 | 15.42 | 18.36 |
| Diluted EPS (Rs.) | 6.64 | 2.97 | 14.64 | 15.42 | 18.28 |
| Cash EPS (Rs.) | 14.56 | 10.26 | 20.81 | 20.17 | 22.16 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 82.99 | 76.28 | 75.16 | 62.51 | 48.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 82.99 | 76.28 | 75.16 | 62.51 | 48.47 |
| Revenue From Operations / Share (Rs.) | 103.05 | 93.53 | 112.14 | 91.85 | 89.70 |
| PBDIT / Share (Rs.) | 20.69 | 14.91 | 29.67 | 26.72 | 29.34 |
| PBIT / Share (Rs.) | 12.71 | 7.78 | 23.65 | 22.04 | 25.52 |
| PBT / Share (Rs.) | 8.99 | 4.39 | 20.59 | 20.17 | 24.25 |
| Net Profit / Share (Rs.) | 6.58 | 3.12 | 14.79 | 15.49 | 18.33 |
| NP After MI And SOA / Share (Rs.) | 6.65 | 2.98 | 14.67 | 15.40 | 18.33 |
| PBDIT Margin (%) | 20.07 | 15.94 | 26.45 | 29.09 | 32.70 |
| PBIT Margin (%) | 12.33 | 8.31 | 21.09 | 23.99 | 28.44 |
| PBT Margin (%) | 8.71 | 4.68 | 18.35 | 21.95 | 27.03 |
| Net Profit Margin (%) | 6.38 | 3.33 | 13.18 | 16.86 | 20.43 |
| NP After MI And SOA Margin (%) | 6.45 | 3.18 | 13.08 | 16.76 | 20.43 |
| Return on Networth / Equity (%) | 8.01 | 3.90 | 19.56 | 24.69 | 37.86 |
| Return on Capital Employeed (%) | 11.82 | 7.94 | 24.37 | 27.63 | 41.57 |
| Return On Assets (%) | 3.83 | 1.91 | 10.31 | 11.87 | 17.10 |
| Long Term Debt / Equity (X) | 0.14 | 0.19 | 0.18 | 0.17 | 0.16 |
| Total Debt / Equity (X) | 0.60 | 0.60 | 0.48 | 0.51 | 0.50 |
| Asset Turnover Ratio (%) | 0.62 | 0.62 | 0.82 | 0.76 | 1.02 |
| Current Ratio (X) | 1.22 | 1.23 | 1.42 | 1.25 | 1.25 |
| Quick Ratio (X) | 0.67 | 0.63 | 0.73 | 0.59 | 0.61 |
| Inventory Turnover Ratio (X) | 2.94 | 2.86 | 1.51 | 1.40 | 1.95 |
| Dividend Payout Ratio (NP) (%) | 12.03 | 53.67 | 13.60 | 10.37 | 7.62 |
| Dividend Payout Ratio (CP) (%) | 5.47 | 15.80 | 9.64 | 7.95 | 6.31 |
| Earning Retention Ratio (%) | 87.97 | 46.33 | 86.40 | 89.63 | 92.38 |
| Cash Earning Retention Ratio (%) | 94.53 | 84.20 | 90.36 | 92.05 | 93.69 |
| Interest Coverage Ratio (X) | 5.55 | 4.39 | 9.68 | 14.26 | 23.10 |
| Interest Coverage Ratio (Post Tax) (X) | 2.76 | 1.92 | 5.82 | 9.27 | 15.43 |
| Enterprise Value (Cr.) | 35759.58 | 23483.39 | 17717.09 | 33370.29 | 20697.57 |
| EV / Net Operating Revenue (X) | 6.44 | 4.66 | 2.93 | 6.76 | 4.30 |
| EV / EBITDA (X) | 32.07 | 29.21 | 11.09 | 23.24 | 13.15 |
| MarketCap / Net Operating Revenue (X) | 5.96 | 4.19 | 2.61 | 6.42 | 4.04 |
| Retention Ratios (%) | 87.96 | 46.32 | 86.39 | 89.62 | 92.37 |
| Price / BV (X) | 7.40 | 5.14 | 3.91 | 9.46 | 7.48 |
| Price / Net Operating Revenue (X) | 5.96 | 4.19 | 2.61 | 6.42 | 4.04 |
| EarningsYield | 0.01 | 0.01 | 0.05 | 0.02 | 0.05 |
After reviewing the key financial ratios for Laurus Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 6.65. This value is within the healthy range. It has increased from 2.98 (Mar 24) to 6.65, marking an increase of 3.67.
- For Diluted EPS (Rs.), as of Mar 25, the value is 6.64. This value is within the healthy range. It has increased from 2.97 (Mar 24) to 6.64, marking an increase of 3.67.
- For Cash EPS (Rs.), as of Mar 25, the value is 14.56. This value is within the healthy range. It has increased from 10.26 (Mar 24) to 14.56, marking an increase of 4.30.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 82.99. It has increased from 76.28 (Mar 24) to 82.99, marking an increase of 6.71.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 82.99. It has increased from 76.28 (Mar 24) to 82.99, marking an increase of 6.71.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 103.05. It has increased from 93.53 (Mar 24) to 103.05, marking an increase of 9.52.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 20.69. This value is within the healthy range. It has increased from 14.91 (Mar 24) to 20.69, marking an increase of 5.78.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.71. This value is within the healthy range. It has increased from 7.78 (Mar 24) to 12.71, marking an increase of 4.93.
- For PBT / Share (Rs.), as of Mar 25, the value is 8.99. This value is within the healthy range. It has increased from 4.39 (Mar 24) to 8.99, marking an increase of 4.60.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 6.58. This value is within the healthy range. It has increased from 3.12 (Mar 24) to 6.58, marking an increase of 3.46.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 6.65. This value is within the healthy range. It has increased from 2.98 (Mar 24) to 6.65, marking an increase of 3.67.
- For PBDIT Margin (%), as of Mar 25, the value is 20.07. This value is within the healthy range. It has increased from 15.94 (Mar 24) to 20.07, marking an increase of 4.13.
- For PBIT Margin (%), as of Mar 25, the value is 12.33. This value is within the healthy range. It has increased from 8.31 (Mar 24) to 12.33, marking an increase of 4.02.
- For PBT Margin (%), as of Mar 25, the value is 8.71. This value is below the healthy minimum of 10. It has increased from 4.68 (Mar 24) to 8.71, marking an increase of 4.03.
- For Net Profit Margin (%), as of Mar 25, the value is 6.38. This value is within the healthy range. It has increased from 3.33 (Mar 24) to 6.38, marking an increase of 3.05.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.45. This value is below the healthy minimum of 8. It has increased from 3.18 (Mar 24) to 6.45, marking an increase of 3.27.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.01. This value is below the healthy minimum of 15. It has increased from 3.90 (Mar 24) to 8.01, marking an increase of 4.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.82. This value is within the healthy range. It has increased from 7.94 (Mar 24) to 11.82, marking an increase of 3.88.
- For Return On Assets (%), as of Mar 25, the value is 3.83. This value is below the healthy minimum of 5. It has increased from 1.91 (Mar 24) to 3.83, marking an increase of 1.92.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 0.2. It has decreased from 0.19 (Mar 24) to 0.14, marking a decrease of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.60. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.60.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.62. There is no change compared to the previous period (Mar 24) which recorded 0.62.
- For Current Ratio (X), as of Mar 25, the value is 1.22. This value is below the healthy minimum of 1.5. It has decreased from 1.23 (Mar 24) to 1.22, marking a decrease of 0.01.
- For Quick Ratio (X), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 1. It has increased from 0.63 (Mar 24) to 0.67, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 4. It has increased from 2.86 (Mar 24) to 2.94, marking an increase of 0.08.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 12.03. This value is below the healthy minimum of 20. It has decreased from 53.67 (Mar 24) to 12.03, marking a decrease of 41.64.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.47. This value is below the healthy minimum of 20. It has decreased from 15.80 (Mar 24) to 5.47, marking a decrease of 10.33.
- For Earning Retention Ratio (%), as of Mar 25, the value is 87.97. This value exceeds the healthy maximum of 70. It has increased from 46.33 (Mar 24) to 87.97, marking an increase of 41.64.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.53. This value exceeds the healthy maximum of 70. It has increased from 84.20 (Mar 24) to 94.53, marking an increase of 10.33.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.55. This value is within the healthy range. It has increased from 4.39 (Mar 24) to 5.55, marking an increase of 1.16.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.76. This value is below the healthy minimum of 3. It has increased from 1.92 (Mar 24) to 2.76, marking an increase of 0.84.
- For Enterprise Value (Cr.), as of Mar 25, the value is 35,759.58. It has increased from 23,483.39 (Mar 24) to 35,759.58, marking an increase of 12,276.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 6.44. This value exceeds the healthy maximum of 3. It has increased from 4.66 (Mar 24) to 6.44, marking an increase of 1.78.
- For EV / EBITDA (X), as of Mar 25, the value is 32.07. This value exceeds the healthy maximum of 15. It has increased from 29.21 (Mar 24) to 32.07, marking an increase of 2.86.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.96. This value exceeds the healthy maximum of 3. It has increased from 4.19 (Mar 24) to 5.96, marking an increase of 1.77.
- For Retention Ratios (%), as of Mar 25, the value is 87.96. This value exceeds the healthy maximum of 70. It has increased from 46.32 (Mar 24) to 87.96, marking an increase of 41.64.
- For Price / BV (X), as of Mar 25, the value is 7.40. This value exceeds the healthy maximum of 3. It has increased from 5.14 (Mar 24) to 7.40, marking an increase of 2.26.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.96. This value exceeds the healthy maximum of 3. It has increased from 4.19 (Mar 24) to 5.96, marking an increase of 1.77.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Laurus Labs Ltd:
- Net Profit Margin: 6.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.82% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.01% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.76
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.67
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 68.5 (Industry average Stock P/E: 47.43)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.6
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Laurus Enclave, Plot Office 01, Edulapakabonangi Village, Vishakapatnam Andhra Pradesh 531021 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Ravindranath Kancherla | Non Exe.Chairman&Ind.Director |
| Mr. V V Ravi Kumar | Executive Director & CFO |
| Dr. Satyanarayana Chava | Executive Director & CEO |
| Ms. Soumya Chava | Executive Director |
| Dr. C V Lakshmana Rao | Executive Director |
| Mr. Krishna Chaitanya Chava | Executive Director |
| Mrs. Aruna Rajendra Bhinge | Independent Director |
| Mr. Karnam Sekar | Independent Director |
| Dr. Rajesh Koshy Chandy | Independent Director |
| Mr. Ramesh Subrahmanian | Independent Director |
FAQ
What is the intrinsic value of Laurus Labs Ltd?
Laurus Labs Ltd's intrinsic value (as of 25 January 2026) is ₹379.87 which is 62.61% lower the current market price of ₹1,016.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹54,871 Cr. market cap, FY2025-2026 high/low of ₹1,141/501, reserves of ₹4,810 Cr, and liabilities of ₹8,692 Cr.
What is the Market Cap of Laurus Labs Ltd?
The Market Cap of Laurus Labs Ltd is 54,871 Cr..
What is the current Stock Price of Laurus Labs Ltd as on 25 January 2026?
The current stock price of Laurus Labs Ltd as on 25 January 2026 is ₹1,016.
What is the High / Low of Laurus Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Laurus Labs Ltd stocks is ₹1,141/501.
What is the Stock P/E of Laurus Labs Ltd?
The Stock P/E of Laurus Labs Ltd is 68.5.
What is the Book Value of Laurus Labs Ltd?
The Book Value of Laurus Labs Ltd is 91.1.
What is the Dividend Yield of Laurus Labs Ltd?
The Dividend Yield of Laurus Labs Ltd is 0.12 %.
What is the ROCE of Laurus Labs Ltd?
The ROCE of Laurus Labs Ltd is 9.47 %.
What is the ROE of Laurus Labs Ltd?
The ROE of Laurus Labs Ltd is 7.75 %.
What is the Face Value of Laurus Labs Ltd?
The Face Value of Laurus Labs Ltd is 2.00.